167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial
| Autor: | De La Motte Rouge, T., Frenel, J-S., Hardy-Bessard, A-C., Bachelot, T., Pistilli, B., Delaloge, S., Deiana, L., Del Piano, F., Genet, D., Gardner, M., Legouffe, E., Levache, C.B., Orfeuvre, H., Valmar, C., Venat, L., Zannetti, A., Le Scodan, R., Dalenc, F., Berger, D., Bidard, F.C. |
|---|---|
| Zdroj: | In Annals of Oncology May 2022 33 Supplement 3:S200-S200 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|